Sentences with phrase «share purchase warrant»

Each unit consists of one common share of the company and one - half of one common share purchase warrant.

Bottom line: The company — which is one of the largest privately held cannabis companies in Canada — will issue between 20.5 million and 27.4 million units, made up of a common share and a half - share purchase warrant, at $ 3.65.

Each Unit will be comprised of one common share of the Company and one non-transferable common share purchase warrant.

Each Unit consists of one common share (a «Common Share») and one - half of one common share purchase warrant (each whole warrant being a «Warrant»).

11-18-2005 2005 Drilling Program Completed on Caledonia's Mulonga Plain Joint Venture 11-14-2005 Caledonia Mining 3rd Quarter Results 2005 10-13-2005 Available online: Webcast of presentation to the Minesite Forum 10-11-2005 London: Presentation to the Minesite Forum 09-14-2005 Caledonia amends terms of share purchase warrants 09-13-2005 Caledonia and Motapa announce 11 drill targets at Mulonga Plain Kashiji Plain analytical results confirm possible local source 08-15-2005 Caledonia Mining signs a Memorandum of Understanding with a South African Black Economic Empowerment Consortium 08-12-2005 Caledonia Mining Second Quarter Results 2005 08-11-2005 Caledonia Mining Second Quarter Results Conference Call and Webcast 07-18-2005 Caledonia announces Summer Drilling Program on Kikerk Lake Property, Nunavut 06-22-2005 Caledonia Mining Corporation announces Admission to the AIM Market of the London Stock Exchange and # 1.57 million placing 06-13-2005 Caledonia Mining signs a Letter of Intent with a Cobalt Refinery to supply 3 % of total annual world production 05-16-2005 Caledonia Mining 1st Quarter Results 2005 05-06-2005 Caledonia Annual Meeting set for Tuesday May 10th 2005 05-05-2005 Caledonia Mining Granted Prospecting Right for Grasvally and Will Commence the Drilling Program by Mid May 2005 03-29-2005 Caledonia Mining 4th Quarter and 2004 Annual Results 03-23-2005 Caledonia Mining Fourth Quarter and Annual results Conference call & webcast 03-08-2005 Mulonga Plain JV Exploration Work Program Update 02-23-2005 Caledonia Mining Appoints New Chairman 01-31-2005 Caledonia updates diamond exploration results at Mulonga Plain joint venture in Zambia.

Not exact matches

The shares carried a 6 % dividend, but the deal's richest prize was a warrant enabling Buffett to purchase 700 million shares at $ 7.14 each until September of 2021.

As well, NAC has issued to Second Cup warrants to purchase 5,000,000 common shares of the company, at an exercise price of 91 cents per share.

Investors love warrants because they offer an extra chance to share in a company's upside potential — in cases in which the warrant is exercisable at a preset purchase price that turns out to be less than the stock's market value.

Instead, if the investor is purchasing $ 5,000 worth of stock at a warrant - conversion price of $ 2,000, the company subtracts the cost of the conversion and actually turns over only $ 3,000 worth of shares to its investor.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Vesting of the warrant shares is subject to Comcast achieving certain milestones and purchase volume commitments, and therefore the accounting guidance requires that the value of the warrant be recorded as a reduction in the Company's net revenues.

Each whole warrant entitles its holder to purchase one share of the

(e) As of the date hereof, (i) 294,670 shares of Series A-4 Preferred Stock are reserved for issuance upon the exercise of outstanding warrants to purchase shares of Series A-4 Preferred Stock (the «Series A-4 Warrants»), and (ii) 40,000 shares of Common Stock are reserved for warrants to purchase shares of Series A-4 Preferred Stock (the «Series A-4 Warrants»), and (ii) 40,000 shares of Common Stock are reserved for Warrants»), and (ii) 40,000 shares of Common Stock are reserved for issuance

Following the expiration of the lock - up agreements referred to above, stockholders owning an aggregate of up to 248,396,604 shares of our Class B common stock (including shares issuable pursuant to the exercise of warrants to purchase shares of our capital stock that were outstanding as of September 30, 2015) can require us to register shares of our capital stock owned by them for public sale in the United States.

After the completion of this offering, the holders of up to 248,396,604 shares of our common stock (including shares issuable pursuant to the exercise of warrants to purchase shares of our capital stock that were outstanding as of September 30, 2015) will be entitled to certain rights with respect to the registration of such shares under the Securities Act.

That October, Buffett exercised all of its warrants to purchase 10.7 million shares of GE's common stock, a position valued at $ 264.76 million based on the closing price on the date the shares were delivered.

After the completion of this offering, the holders of up to 248,396,604 shares of our Class B common stock (including shares issuable pursuant to the exercise of warrants to purchase shares of our capital stock that were outstanding as of September 30, 2015) will be entitled to certain «piggyback» registration rights.

warrants to purchase shares of our common stock or any securities that are convertible into, exchangeable for, or that represent the right to receive, shares of our common stock or any such substantially similar securities, or publicly disclose the intention to make any offer, sale, pledge, disposition or filing; or

(d) by causing Retrophin to pay cash to himself, Biestek, and Fernandez so that he would not have to invest $ 731,778 of his own funds in the February PIPE, and by using PIPE proceeds in contravention of the terms of the Securities Purchase Agreement to fund investments by Shkreli, Biestek and Fernandez, resulting in an additional benefit to Shkreli alone of $ 360,000 in cash and 180,000 Retrophin shares and warrants worth more than $ 5.3 million (at current market prices).

As of September 30, 2014, the holders of 52,132,350 shares of our common stock, including our common stock issuable in connection with the automatic conversion of all outstanding shares of our convertible preferred stock into shares of our common stock and the holder of a warrant to purchase 6,500,000 shares of our common stock, are entitled to rights with respect to the registration of their shares following this offering under the Securities Act.

Unlike stock options, warrants tend to provide an option to purchase the most recent class of shares (rather than common shares).

This convertible preferred stock warrant will become a warrant to purchase shares of our common stock upon the closing of this offering.

in the case of our directors, officers, and security holders, (i) the receipt by the locked - up party from us of shares of Class A common stock or Class B common stock upon (A) the exercise or settlement of stock options or RSUs granted under a stock incentive plan or other equity award plan described in this prospectus or (B) the exercise of warrants outstanding and which are described in this prospectus, or (ii) the transfer of shares of Class A common stock, Class B common stock, or any securities convertible into Class A common stock or Class B common stock upon a vesting or settlement event of our securities or upon the exercise of options or warrants to purchase our securities on a «cashless» or «net exercise» basis to the extent permitted by the instruments representing such options or warrants (and any transfer to us necessary to generate such amount of cash needed for the payment of taxes, including estimated taxes, due as a result of such vesting or exercise whether by means of a «net settlement» or otherwise) so long as such «cashless exercise» or «net exercise» is effected solely by the surrender of outstanding stock options or warrants (or the Class A common stock or Class B common stock issuable upon the exercise thereof) to us and our cancellation of all or a portion thereof to pay the exercise price or withholding tax and remittance obligations, provided that in the case of (i), the shares received upon such exercise or settlement are subject to the restrictions set forth above, and provided further that in the case of (ii), any filings under Section 16 (a) of the Exchange Act, or any other public filing or disclosure of such transfer by or on behalf of the locked - up party, shall clearly indicate in the footnotes thereto that such transfer of shares or securities was solely to us pursuant to the circumstances described in this bullet point;

the conversion of all outstanding warrants to purchase shares of convertible preferred stock into warrants to purchase the same number of shares of Class B common stock immediately prior to the completion of this offering;

In September 2012, the Registrant issued warrants to purchase 1,080,000 shares of its Series C convertible preferred stock at an exercise price of $ 1.00 per share to two accredited investors.

We, our officers and directors, and holders of substantially all of the outstanding shares of our common stock including the selling stockholders, have agreed with the underwriters, subject to certain exceptions, not to offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of any shares of common stock, options or warrants to purchase shares of common stock or securities convertible into, exchangeable for or that represent the right to receive shares of common stock, whether now owned or hereafter acquired, during the period from the date of this prospectus continuing through the date 180 days after the date of this prospectus, except with the prior written consent of each of Goldman, Sachs & Co., Morgan Stanley & Co..

In connection with this offering, the warrants to purchase shares of our Series B and Series C convertible preferred stock will convert automatically into warrants to purchase a like number of shares of our Class B common stock.

In connection with this financing, the remaining holders of the February 2008 notes and warrants converted their notes into shares of Series E convertible preferred stock and warrants to purchase 866,091 shares of Series E convertible preferred stock.

In February 2008, the registrant issued warrants to purchase an aggregate of 866,091 shares of the registrant's Series E preferred stock to 19 accredited investors at an exercise price of $ 2.5124 per share.

offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of any shares of our common stock, options or warrants to purchase shares of our common stock or securities convertible into, exchangeable for or that represent the right to receive shares of our common stock; or

However, in January 2010, we issued a warrant to the DOE in connection with the closing of the DOE Loan Facility to purchase shares of our Series E convertible preferred stock.

Upon the completion of this offering, we expect that the convertible preferred stock warrants currently outstanding will either be exercised or become warrants to purchase shares of our common stock.

The 2014 Recapitalization Agreement would also provide that under certain circumstances we may be required to issue new warrants to purchase shares of our common stock at an exercise price per share of $ 0.01 rather than issue shares of our common stock, in exchange for certain of the Related - Party Notes and Related - Party Wwarrants to purchase shares of our common stock at an exercise price per share of $ 0.01 rather than issue shares of our common stock, in exchange for certain of the Related - Party Notes and Related - Party WarrantsWarrants.

Based on an assumed initial public offering price of $ per share (the midpoint of the price range set forth on the cover of this prospectus), we do not anticipate that any of our existing warrants to purchase common stock would remain outstanding upon the closing of this offering.

The 2014 Recapitalization Agreement would also provide that the remaining Related - Party Warrants to purchase an aggregate of 62,105,000 shares of our common stock would be cancelled in their entirety.

outstanding warrants to purchase shares of our common stock, including our Related - Party Warrants, either (i) would be exchanged for shares of our common stock depending in part on the initial public offering price of this offering, (ii) would be exercised to the extent the exercise price per share provided for therein is less than the initial public offering price of this offering or (iii) would expire or otherwise be cancelwarrants to purchase shares of our common stock, including our Related - Party Warrants, either (i) would be exchanged for shares of our common stock depending in part on the initial public offering price of this offering, (ii) would be exercised to the extent the exercise price per share provided for therein is less than the initial public offering price of this offering or (iii) would expire or otherwise be cancelWarrants, either (i) would be exchanged for shares of our common stock depending in part on the initial public offering price of this offering, (ii) would be exercised to the extent the exercise price per share provided for therein is less than the initial public offering price of this offering or (iii) would expire or otherwise be cancelled; and

our currently outstanding warrants to purchase shares of our common stock, including our Related - Party Warrants, either (i) would be exchanged for shares of our common stock depending in part on the initial public offering price of this offering, (ii) would be exercised to the extent the exercise price per share provided for therein is less than the initial public offering price of this offering or (iii) would expire or otherwise be cancelwarrants to purchase shares of our common stock, including our Related - Party Warrants, either (i) would be exchanged for shares of our common stock depending in part on the initial public offering price of this offering, (ii) would be exercised to the extent the exercise price per share provided for therein is less than the initial public offering price of this offering or (iii) would expire or otherwise be cancelWarrants, either (i) would be exchanged for shares of our common stock depending in part on the initial public offering price of this offering, (ii) would be exercised to the extent the exercise price per share provided for therein is less than the initial public offering price of this offering or (iii) would expire or otherwise be cancelled; and

Based on an assumed initial public offering price of $ per share (the midpoint of the price range set forth on the cover of this prospectus), we estimate that we would issue an aggregate of shares of our common stock in exchange for Related - Party Warrants to purchase shares of common stock.

The Virgin Group and Cyrus Capital also hold the majority of our outstanding warrants to purchase shares of our common stock, which we refer to in this prospectus as the «Related - Party Warrantswarrants to purchase shares of our common stock, which we refer to in this prospectus as the «Related - Party WarrantsWarrants.»

The diluted net income (loss) per share calculations include shares of Class A, Class A-1, and Class B common stock, as well as warrants to purchase shares of Class A and Class C common stock where the warrant exercise price is below the fair value of the underlying common stock and therefore would have a dilutive effect.

Following the 2014 Recapitalization, we may have additional outstanding warrants to purchase shares of our common stock.

The Company has granted the Agents an over-allotment option, exercisable in whole or in part, for a period of 30 days following the closing of the Offering, to purchase up to an additional 4,726,500 Units at $ 3.65 per Unit, 4,726,500 Common Shares at the price of $ 3.62 per Share or 2,363,250 Warrants at the price of $ 0.06 per Warrant, or any combination thereof.

A warrant is a certificate, which gives shareholders the right to purchase future shares within the company either for a specific period of time, within a certain amount of years or they may have the right to purchase these new stock shares at any time.

The syndicate of underwriters has agreed to purchase 22,222,500 units at CA$ 0.90 per unit; one unit includes one common share of the company and one warrant to purchase one share within 24 months at CA$ 1.10.

The warrants could be used to purchase Dell shares for $ 20 in the future.

In February 2016, the Company issued to a service provider a 12 month convertible debentures at 15 % interest with a principal amount of $ 35,000 along with 35,000 3 - year warrants to purchase shares common stock at $ 1.00 per share The convertible debentures are payable at maturity, and convertible at the investor's determination at a price equal to 90 % of the price of a subsequent public underwritten offering if one occurs over $ 5 million, or, if no subsequent offering occurs, at $ 0.75 per share.

The debt component of the offering consists of $ 6 million in non-interest bearing non-convertible original issue discount senior secured debt maturing on February 10, 2019 and warrants to purchase a total of 6,875,000 shares of Common Stock at a fixed exercise price of $ 0.96 per share.

In addition, the Company issued unregistered warrants to purchase a total of 2,660,000 shares of Common Stock at an exercise price of $ 2.00 per share.

In addition, the Company will issue warrants to purchase a total of 1,423,488 shares of Common Stock to the holders of the Preferred Stock at an exercise price of $ 0.96 per share.

In addition, the Company will issue unregistered warrants to purchase a total of 2,660,000 shares of Common Stock at a fixed exercise price of $ 2.00 per share.